In line with these observations, it has been demonstrated that norfenfluramine (a metabolite of the antiobesity drug fenfluramine that exhibits potent 5-HT2B agonist activity) and other 5-HT2B agonists used in the treatment of migraine induce valvular heart disease23–25. Here, HTR2B is linked to migraine disorder.